Author: Ellen
Lilly drug slows Alzheimer’s by 35%, bolstering treatment approach (Links to an external site)
Conquering Alzheimer’s: a look at the therapies of the future (Links to an external site)
Seeking Alzheimer’s clues from few who escape genetic fate (Links to an external site)
Lifetime Achievement Award (Links to an external site)
Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers (Links to an external site)
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
The statement below is in response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD). On January 6th, 2023, the FDA announced approval of lecanemab (an anti-amyloid beta (Aβ) protofibril antibody) through its Accelerated Approval Program for the treatment of mild cognitive impairment […]
FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE (Links to an external site)
Update on the DIAN-TU-002 Primary Prevention Trial
20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab. During the presentation of topline results from GRADUATE I and II studies at the […]